The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Biologics CDMO Global Market Report 2024, the biologics CDMO market is expected to show promising growth in the forecast period.

The biologics Contract Development and Manufacturing Organization (CDMO) market has witnessed substantial growth in recent years, driven by increasing biologics development and outsourcing trends. From $18.44 billion in 2023, the market is projected to reach $21.30 billion in 2024, growing at a CAGR of 15.4%. Looking ahead, it is expected to expand further to $36.54 billion by 2028, with a CAGR of 14.4%. This growth trajectory can be attributed to several factors:

• Biologics Development Surge: Rise in demand for biologic therapies, including biosimilars and biobetters.
• Technological Advancements: Adoption of single-use technologies and continuous manufacturing processes.
• Globalization of Supply Chains: Focus on supply chain resilience and risk mitigation.
• Regulatory Harmonization: Streamlined processes for expedited approvals.

Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth

The increasing demand for cell and gene therapy is a significant driver for the biologics CDMO market. These therapies represent innovative approaches in treating diseases at the genetic or cellular level, offering solutions for previously incurable conditions. Biologic CDMOs play a crucial role in supporting these therapies by providing expertise in handling living cells, viral vectors, and genetic materials. This expertise ensures safe and efficient production while navigating complex regulatory landscapes. As of January 2023, the gene, cell, and RNA therapy pipeline showed promising growth, indicating a robust demand for such innovative treatments.

View More On The Biologics CDMO Market Report 2024 – https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Advancements In Biologics CDMO
Leading companies in the biologics CDMO sector are pioneering advanced solutions to enhance biopharmaceutical development and manufacturing capabilities. For instance, Lonza Group introduced GS Effex cell lines in November 2023, designed to produce antibodies with enhanced potency by eliminating fucose, a sugar molecule. This advancement addresses challenges in immunotherapy, offering scalable and productive solutions from discovery to commercial stages.

Bora Pharmaceuticals Expands Global Footprint
In a strategic move to bolster its global presence, Bora Pharmaceuticals acquired Eden Biologics Inc.’s CDMO assets in May 2022 for $100 million. This acquisition underscores Bora’s commitment to expanding its capabilities in biologics, macromolecules, and cell and gene therapy markets, positioning itself as a key player in the evolving biologics CDMO landscape.

Market Segmentation and Regional Insights
The biologics CDMO market is segmented by cell type (mammalian, non-mammalian) and product type (biologics, biosimilars). North America led the market in 2023, driven by technological advancements and robust healthcare infrastructure. Meanwhile, Asia-Pacific is poised to witness the fastest growth during the forecast period, supported by increasing investments in biomanufacturing and favorable regulatory frameworks.

Key Players in the Biologics CDMO Market
Major companies shaping the biologics CDMO landscape include AbbVie Inc., Thermo Fisher Scientific Inc., Lonza Group Ltd., and WuXi Biologics (Cayman) Inc. These entities are pivotal in driving innovation, expanding capabilities, and meeting the rising demand for biologic therapies worldwide.

In conclusion, the biologics CDMO market is poised for substantial growth, fueled by advancements in biotechnology, rising demand for innovative therapies, and strategic expansions by key industry players. As the market continues to evolve, stakeholders must adapt to technological innovations and regulatory shifts to capitalize on emerging opportunities.

Request A Sample Of The Global Biologics CDMO Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=14056&type=smp